International Leukemia/Lymphoma Target Board (iLTB)

The iLTB is an international platform of experts, such as oncologists and biologists, that aims to make access to drug trials for children with relapsed or refractory leukemia and lymphoma as standardized as possible. The characteristics of the child-specific leukemia/lymphoma (what we call the tumor profile) are discussed in an anonymized way within an international panel of experts. The iLTB advises on possible treatment options.

Health care providers:

Please find more information here

Recruiting

Who can participate

Children, adolescents, and young adults diagnosed with relapsed or refractory hematological malignancies who are below the age of 25
No standard of care treatment is available for them
Health care providers: please find more information here

Goal

To discuss the tumor profile with an international group of experts in the fields of biology and new drugs called the "international Leukemia/Lymphoma Target Board" (iLTB).

The tumor profile provides insight into the characteristics of the child's leukemia/lymphoma cells. This may include abnormalities of the leukemia cells (inside and/or at the cell surface) or sensitivity to a drug in laboratory tests. These characteristics may offer the possibility to treat the malignant cells differently with new drugs now that the child's disease is not responding to standard treatment options.

To this end, the platform evaluates the characteristics of the leukemia/lymphoma cells and treatments already given, and then advises on possible appropriate clinical trials or alternatives if a clinical trial is not available.

Background

The origin of many forms of (childhood) cancer lies in the biological properties of the leukemia/lymphoma cells. The biological characteristics of the leukemia/lymphoma cells are determined as part of standard diagnostic procedures (called 'tumor profile'). These biological features are unique to each patient and may explain why the disease progresses differently in each patient and why patients may respond differently to treatment.

The choice of treatment can be very difficult when the disease has become unresponsive (refractory) or has come back (relapse) and standard treatment options are lacking. Therefore, we want to discuss the child's leukemia/lymphoma profile with an international group of experts in the fields of biology, clinical trials, new drugs, and specific disease experts, called the international Leukemia/Lymphoma Target Board (iLTB).

Discussing the tumor profile offers the opportunity for some children to be treated with a drug that more closely targets their tumor-specific features. In recent years, more targeted therapies and new drugs have been developed. However, this is not yet accepted as standard of care treatment, and it is not always clear whether such a drug is effective to treat relapsing or refractory leukemia/lymphoma. This is because of the rarity of these diseases and the variation in biological features in each child's leukemia/lymphoma, or because the new drug has not yet been extensively tested in childhood leukemia/lymphoma.

In order to participate in a study please refer to your/your child’s doctor.

Last reviewed

March 23, 2026

Study details
Official title
international Leukemia/Lymphoma Target Board (iLTB): International platform of experts to discuss possible treatment options of children, adolescents and young adults with relapsed/refractory leukemia or lymphoma.
Cancer type
- Leukemia
- Lymphoma (particularly lymphoblastic lymphoma)
Maximum number of patients
International 500 patients in 6 years
Start date
December 6, 2022
Status
Open
Local principal investigator
Dr. M. Luesink
Sponsor
Princess Máxima Center for pediatric oncology
Approval
This study has been reviewed and approved by the internal scientific committee (Clinical Research Committee) of the Princess Máxima Center. An accredited medical research ethics committee waived the need for official approval according to the Medical Research Involving Human Subjects Act (WMO), and is therefore not further involved in the review of the research. This is only done for studies with low risk or low patient burden. More information can be found at: CCMO.
Trial registry number
ClinialTrials.gov NCT05270096

The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.